What is the address of RNA Pioneering?

The registered office of RNA Pioneering is located at Rijvisschestraat 120, 9052 Gent.

Is RNA Pioneering still active?

Yes. According to the CBE (29 October 2026) RNA Pioneering is active, legal situation “Normale toestand”, started on 29 December 1995.

Is RNA Pioneering registered on Peppol?

Yes, RNA Pioneering is registered on the Peppol network with ID 0208:0456792695.

What is the enterprise number of RNA Pioneering?

The enterprise number of RNA Pioneering is BE0456792695.

When was RNA Pioneering founded?

RNA Pioneering was founded on 29 December 1995.

Who are the directors of RNA Pioneering?

According to the 2025 annual accounts, the directors of RNA Pioneering are: Bellevue NV.

Is RNA Pioneering a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 29 December 1995; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did RNA Pioneering make in 2025?

RNA Pioneering recorded a loss after taxes of € 128,247 in financial year 2025.

What is the revenue of RNA Pioneering?

As a small company, RNA Pioneering is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -111,461.

RNA Pioneering (Public Limited) - Gent - BE0456792695

Q: What does RNA Pioneering do?

RNA Pioneering is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Public Limited, started on 29 December 1995, 1 establishment.

Dossier RNA Pioneering, printed on 29 October 2026 from databakkes.be/en/0456792695/rna-pioneering. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

RNA Pioneering from Gent, company number BE0456792695, closed financial year 2025 with a result of € -128,247 after tax. For that financial year RNA Pioneering recorded a gross margin of € -111,461 and equity of € 5.5 million. Compared with financial year 2024, the result moved from € -125,999 to € -128,247. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 16, 2026.

What it is worth Healthy

€ 5.5 million

▼ 2% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -128,247

▼ 2 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 198,540

▲ € 163,322 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -2.2 million.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 117,829

▲ 229% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 207,296 Gross margin 2022: € 207,296 First fiscal year in the series	€ -314,329 Gross margin 2023: € -314,329 ▼ € 521,626 vs 2022 (€ 207,296) Unfavourable step	€ -81,159 Gross margin 2024: € -81,159 ▲ € 233,171 vs 2023 (€ -314,329) Favourable step	€ -111,461 Gross margin 2025: € -111,461 ▼ € 30,303 vs 2024 (€ -81,159) Unfavourable step	▼ € 30,303
Profit after taxes	€ 145,603 Profit after taxes 2022: € 145,603 First fiscal year in the series	€ -350,295 Profit after taxes 2023: € -350,295 ▼ € 495,898 vs 2022 (€ 145,603) Unfavourable step	€ -125,999 Profit after taxes 2024: € -125,999 ▲ € 224,295 vs 2023 (€ -350,295) Favourable step	€ -128,247 Profit after taxes 2025: € -128,247 ▼ € 2,248 vs 2024 (€ -125,999) Unfavourable step	▼ € 2,248
Equity	€ 1,152,803 Equity 2022: € 1,152,803 First fiscal year in the series	€ 5,762,888 Equity 2023: € 5,762,888 ▲ € 4.6 million vs 2022 (€ 1,152,803) Favourable step	€ 5,636,889 Equity 2024: € 5,636,889 ▼ 2% vs 2023 (€ 5,762,888) Unfavourable step	€ 5,508,642 Equity 2025: € 5,508,642 ▼ 2% vs 2024 (€ 5,636,889) Unfavourable step	▼ 2%
Total debts	€ 10,075 Total debts 2022: € 10,075 First fiscal year in the series	€ 74,230 Total debts 2023: € 74,230 ▲ € 64,155 vs 2022 (€ 10,075) Unfavourable step	€ 35,844 Total debts 2024: € 35,844 ▼ 52% vs 2023 (€ 74,230) Favourable step	€ 117,829 Total debts 2025: € 117,829 ▲ 229% vs 2024 (€ 35,844) Unfavourable step	▲ 229%
Cash	€ 110,500 Cash 2022: € 110,500 First fiscal year in the series	€ 111,172 Cash 2023: € 111,172 ▲ 1% vs 2022 (€ 110,500) Favourable step	€ 35,218 Cash 2024: € 35,218 ▼ 68% vs 2023 (€ 111,172) Unfavourable step	€ 198,540 Cash 2025: € 198,540 ▲ € 163,322 vs 2024 (€ 35,218) Favourable step	▲ € 163,322
Retained profit	€ -1,597,197 Retained profit 2022: € -1,597,197 First fiscal year in the series	€ -1,947,492 Retained profit 2023: € -1,947,492 ▼ € 350,295 vs 2022 (€ -1,597,197) Unfavourable step	€ -2,073,491 Retained profit 2024: € -2,073,491 ▼ € 125,999 vs 2023 (€ -1,947,492) Unfavourable step	€ -2,201,738 Retained profit 2025: € -2,201,738 ▼ € 128,247 vs 2024 (€ -2,073,491) Unfavourable step	▼ € 128,247
Bank debt	€ 4,753 Bank debt 2022: € 4,753 First fiscal year in the series	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 4,753) Favourable step	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 1,162,878 Balance sheet total 2022: € 1,162,878 First fiscal year in the series	€ 5,837,118 Balance sheet total 2023: € 5,837,118 ▲ € 4.7 million vs 2022 (€ 1,162,878) Unchanged	€ 5,672,732 Balance sheet total 2024: € 5,672,732 ▼ 3% vs 2023 (€ 5,837,118) Unchanged	€ 5,626,471 Balance sheet total 2025: € 5,626,471 ▼ 1% vs 2024 (€ 5,672,732) Unchanged	▼ 1%

Key figures of RNA Pioneering, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to RNA Pioneering?

What happened at RNA Pioneering in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 Bellevue NV stepped down as director. NBB
Jul 16, 2026 New annual accounts for financial year 2025: loss of € 128,247. Source: NBB ↗
2022 Bellevue NV became a director. NBB
Feb 18, 1999 New establishment in Gent. KBO
Dec 29, 1995 Start of the company according to the CBE. KBO

In short

From € 145,603 profit in 2022 to € 128,247 loss in 2025.

Paid € 1,300 in corporate taxes since 2022.

Best year ever: 2022, with € 145,603 profit.

Original PDFs at the National Bank ↗

Management

BELLEVUE 43.5%

MASC-INVEST 20%

SEASTAR CAPITAL 20%

BELINVEST 20%

The stake of BELLEVUE, MASC-INVEST, SEASTAR CAPITAL, BELINVEST comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

RNA Pioneering

Ziphius 59%

The shares are held by BELLEVUE (43.5%), MASC-INVEST (20%), SEASTAR CAPITAL (20%) and BELINVEST (20%). It owns 59% of Ziphius itself.

Directors

According to the 2025 annual accounts

Bellevue NV

Director · represented by Christiaan Cardon

Also active at: BORDEAUX I

since 2022 · until 2027

Shareholders

43.5%

20%

20%

20%

Participations

Ziphius

59%

Establishments

Establishment units

Physical locations of this company

Registered office

Rijvisschestraat 120

9052 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.

All companies at this address →

DOING WELL BY DOING GOOD

€ 27,550 gross margin · 2025

Ziphius same network

€ 2.4 million gross margin · 2025

CARDON BIO

€ 25,626 gross margin · 2025

CELL-CELL BIO

€ 777,487 gross margin · 2025

BORDEAUX I same network

€ -3,685 gross margin · 2025

+1 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0456.792.695

VAT number

BE 0456.792.695

Registered office

Rijvisschestraat 120, 9052 Gent

Names & denominations

RNA Pioneering

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

29 December 1995

Peppol

Active · Active since 24 Nov 2023

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Groothandel in farmaceutische producten

Groothandel in farmaceutische en medische artikelen

Vervaardiging van geneesmiddelen

View on CBE Public ↗ Annual accounts (NBB) ↗

RNA Pioneering

Warning lights

Financials

What happened to RNA Pioneering?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions